Pfizer Inc (PFE)

33.76
0.14 0.40
NYSE : Health Care
Prev Close 33.62
Open 33.57
Day Low/High 33.48 / 33.80
52 Wk Low/High 28.74 / 37.39
Volume 4.23M
Avg Volume 25.49M
Exchange NYSE
Shares Outstanding 6.07B
Market Cap 204.02B
EPS 1.20
P/E Ratio 16.09
Div & Yield 1.28 (3.80%)

Latest News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

Stock Investors May Be Rooting for a Trump Overseas Tax Holiday, But Bondholders Should Be Wary

Stock Investors May Be Rooting for a Trump Overseas Tax Holiday, But Bondholders Should Be Wary

Companies like Apple, Microsoft and Cisco can afford aggressive buybacks and dividends, but activists could force others with offshore cash to choose between equity and debt holders.

New Data In Crohn's Disease Patients Shows Similar Efficacy And Safety Profiles For INFLECTRA® And REMICADE®a

New Data In Crohn's Disease Patients Shows Similar Efficacy And Safety Profiles For INFLECTRA® And REMICADE®a

Data announced jointly today by Pfizer Inc. (NYSE:PFE) and Celltrion Healthcare, at the 12 th Congress of the European Crohn's and Colitis Organisation (ECCO), showed that for patients with moderate-to-severe Crohn's...

Here Comes Pfizer's Powerful Breakout

Here Comes Pfizer's Powerful Breakout

The charts say so.

Pfizer Announces Top-Line Results From The Oral Strategy Trial Of XELJANZ® (tofacitinib Citrate) Compared To Humira® (adalimumab)

Pfizer Announces Top-Line Results From The Oral Strategy Trial Of XELJANZ® (tofacitinib Citrate) Compared To Humira® (adalimumab)

Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA).

Stocks With A Heart

Stocks With A Heart

Here are three stock picks with a romantic spin

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.

Grading Our Portfolio Moves

How did we do with our recommendations?

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Eli Lilly Is Great Stock to Buy Now

Eli Lilly Is Great Stock to Buy Now

Here's why the pharmaceutical company is a solid addition to your portfolio.

How I'd Play Our Current Portfolio (Part IV)

Here's my take and suggested actions for Owens-Illinois, Pfizer and PPL.

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Tom Price will now head the Department of Health and Human Services.

Portfolio Update: AbbVie, Pfizer and Sonoco Report Earnings; and Don't Miss These Must-Own Dates!

An update of earnings, payout dates and upcoming dividend reminders.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Relationship Expert Teams Up With Pfizer To Address Intimacy And Relationship Issues For People Living With Chronic Diseases

Relationship Expert Teams Up With Pfizer To Address Intimacy And Relationship Issues For People Living With Chronic Diseases

Nationally-recognized relationship expert and author, Logan Levkoff, Ph.

BlackRock, Dave and Busters, Allergan, Callaway Golf: 'Mad Money' Lightning Round

BlackRock, Dave and Busters, Allergan, Callaway Golf: 'Mad Money' Lightning Round

Jim Cramer is bullish on BlackRock and Dave and Busters, but bearish on Callaway Golf and AU Optronics.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Is This Market in Trump-Bubble Territory? Cramer's 'Mad Money' Recap (Wednesday 2/8/17)

Is This Market in Trump-Bubble Territory? Cramer's 'Mad Money' Recap (Wednesday 2/8/17)

It's not an over-exuberant Trump bubble, Jim Cramer says, because earnings and fundamentals remain solid.

Biotech Tesaro Climbs on Takeout Reports

Biotech Tesaro Climbs on Takeout Reports

The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.

Allergan's Fourth-Quarter Comments Should Comfort Investors

Allergan's Fourth-Quarter Comments Should Comfort Investors

The company has seemingly reset expectations and is viewed as having an in-development pipeline that covers multiple potential catalysts.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment

Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment

Cellectis is taking another step to move immunotherapy 'off the shelf.'

Pfizer CEO: 'Misinformation About Drug Pricing Is Far Greater Than I've Ever Seen'

Pfizer CEO: 'Misinformation About Drug Pricing Is Far Greater Than I've Ever Seen'

The pharma giant will lever up should a strategic deal opportunity come along, too.

5 Companies That Announced Share Buybacks This Week

5 Companies That Announced Share Buybacks This Week

These five companies announced this week that they will repurchase shares.

Financials Lead Wall Street Higher on Hopes for Relaxed Regulations

Financials Lead Wall Street Higher on Hopes for Relaxed Regulations

The Dow Jones Industrial Average trades above the 20,000 level again on Friday as a pending pause of banking regulations gives the financial sector a boost.

Pfizer Is Returning Even More Cash to Shareholders

Pfizer Is Returning Even More Cash to Shareholders

Pharma giant Pfizer commenced a massive new share buyback program on Friday.

Dow Trades Above 20,000 as Bank Stocks Rally, U.S. Jobs Increase

Dow Trades Above 20,000 as Bank Stocks Rally, U.S. Jobs Increase

The Dow Jones Industrial Average trades above the 20,000 level again on Friday as a potential repeal of banking regulations gives the financial sector a boost.

Stock Futures Hold Higher After U.S. Economy Adds 227,000 Jobs

Stock Futures Hold Higher After U.S. Economy Adds 227,000 Jobs

Stock futures hold higher on Friday after the U.S. economy adds far more jobs in January than anticipated.